ACR Pushes for Patient Interests, Against Spending Cuts

Join the AMA (I Really Mean It)!
The American Medical Association’s House of Delegates voted recently to approve the ACR’s resolution asking the federal government to allow international physicians to have visas processed quickly so they can take care of underserved U.S. patients. Subsequently, the Trump administration made the requested changes just in time for physicians finishing training to apply. The ACR’s ability to propose resolutions on issues related to patient care, our workforce shortage, reimbursement, administrative hassles, etc. is contingent upon having enough ACR members join the AMA. Go here to join or renew your AMA membership.

Thanks for reading. Don’t forget to invest in RheumPAC and make your voice heard on Capitol Hill.

Angus Worthing, MD, FACP, FACR, Chair, Government Affairs Committee, is a practicing rheumatologist in the Washington, D.C., metro area and clinical assistant professor of medicine at Georgetown University.

The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

Rheumatologists may need to downsize and restrict patient care if Congress doesn’t act to block significant cuts to Medicare reimbursement rates totaling 9.75% in 2022.

As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

Marching to the Biosimilar Beat: Questions on Rollout Remain

Speak Up: Ask Congress to Block Medicare Reimbursement Cuts

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

Related Articles